Pharmacogenomic test that predicts response to β2-agonists in adults with asthma is cost effective

Ann Chen Wu; Charlene Gay; Melisa D Rett; Anne L Fuhlbrigge

doi:10.2217/pme.15.23

Pharmacogenomic test that predicts response to β₂-agonists in adults with asthma is cost effective

Per Med. 2015 Nov;12(6):574-584. doi: 10.2217/pme.15.23.

Authors

Ann Chen Wu^{1

2}, Charlene Gay¹, Melisa D Rett¹, Anne L Fuhlbrigge³

Affiliations

¹ Center for Child Health Care Studies, Department of Population Medicine, Harvard Medical School & Harvard Pilgrim Health Care Institute, 133 Brookline Avenue, 6th Floor, Boston, MA 02215-5301, USA.
² Children's Hospital Boston, Boston, MA, USA.
³ Division of Pulmonary & Critical Care Medicine, Brigham & Women's Hospital & Harvard Medical School, Boston, MA, USA.

PMID: 29750604
DOI: 10.2217/pme.15.23

Abstract

Background: Pharmacogenomic tests that predict which asthma patients are likely to respond to β₂-agonists hold promise to improve care for asthma.

Objective: To identify the clinical and economic circumstances under which a pharmacogenomic test that predicts response to β₂-agonists might or might not be an appropriate, cost-effective option.

Methods: We synthesized published data on clinical and economic outcomes in adults 18-35 to project 10-year costs, quality-adjusted life years and cost-effectiveness of pharmacogenomic testing for β₂-agonist response.

Results: Pharmacogenomic testing for β₂-agonist response conferred a cost-effectiveness ratio of $13,700 per quality-adjusted life year gained compared with no testing.

Conclusion: Pharmacogenomic testing for β₂-agonist response in individuals with asthma is potentially cost effective and should be pursued by test developers.

Keywords: asthma; bronchodilators; cost–effectiveness; pharmacogenomics; predictive test; β2 agonists.